Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess Sells 2,940 Shares

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) Director Robert Chess sold 2,940 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $53.13, for a total value of $156,202.20. Following the transaction, the director now owns 18,173 shares in the company, valued at approximately $965,531.49. This represents a 13.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Robert Chess also recently made the following trade(s):

• On Tuesday, January 7th, Robert Chess sold 5,000 shares of Twist Bioscience stock. The shares were sold at an average price of $50.00, for a total value of $250,000.00.
• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total value of $181,682.40.

Twist Bioscience Stock Up 1.5 %

NASDAQ TWST traded up $0.72 during trading on Friday, reaching $47.59. 808,745 shares of the company's stock were exchanged, compared to its average volume of 786,851. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The company has a 50 day moving average price of $48.46 and a two-hundred day moving average price of $45.85. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.54 and a current ratio of 4.96. The stock has a market cap of $2.84 billion, a P/E ratio of -14.08 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm's revenue was up 24.1% compared to the same quarter last year. During the same period last year, the company posted ($0.75) earnings per share. On average, equities research analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience in the third quarter worth $34,000. Van ECK Associates Corp increased its position in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after acquiring an additional 267 shares during the period. Signaturefd LLC lifted its stake in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after purchasing an additional 306 shares during the period. US Bancorp DE raised its stake in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after buying an additional 601 shares during the period. Finally, Beaird Harris Wealth Management LLC bought a new position in shares of Twist Bioscience in the third quarter valued at approximately $95,000.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TWST. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. Scotiabank raised their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a "sector outperform" rating in a report on Tuesday, February 4th. TD Cowen restated a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. Finally, Barclays dropped their target price on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.